Hodgkin lymphoma

From molecular pathogenesis to targeted therapy

Ádám Jóna, A. Illés, Anas Younes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 % of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 % of these patients.

Original languageEnglish
Title of host publicationHematologic Cancers
Subtitle of host publicationFrom Molecular Pathobiology to Targeted Therapeutics
PublisherSpringer Netherlands
Pages181-202
Number of pages22
ISBN (Electronic)9789400750289
ISBN (Print)9789400750272
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Hodgkin Disease
Stem Cell Transplantation
Developed Countries
Lymphoma
B-Lymphocytes
Recurrence
Incidence
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jóna, Á., Illés, A., & Younes, A. (2012). Hodgkin lymphoma: From molecular pathogenesis to targeted therapy. In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics (pp. 181-202). Springer Netherlands. https://doi.org/10.1007/978-94-007-5028-9_10

Hodgkin lymphoma : From molecular pathogenesis to targeted therapy. / Jóna, Ádám; Illés, A.; Younes, Anas.

Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands, 2012. p. 181-202.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jóna, Á, Illés, A & Younes, A 2012, Hodgkin lymphoma: From molecular pathogenesis to targeted therapy. in Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands, pp. 181-202. https://doi.org/10.1007/978-94-007-5028-9_10
Jóna Á, Illés A, Younes A. Hodgkin lymphoma: From molecular pathogenesis to targeted therapy. In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands. 2012. p. 181-202 https://doi.org/10.1007/978-94-007-5028-9_10
Jóna, Ádám ; Illés, A. ; Younes, Anas. / Hodgkin lymphoma : From molecular pathogenesis to targeted therapy. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands, 2012. pp. 181-202
@inbook{dab90d9f8a514200b3482178867edf99,
title = "Hodgkin lymphoma: From molecular pathogenesis to targeted therapy",
abstract = "Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 {\%} of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 {\%} of these patients.",
author = "{\'A}d{\'a}m J{\'o}na and A. Ill{\'e}s and Anas Younes",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-94-007-5028-9_10",
language = "English",
isbn = "9789400750272",
pages = "181--202",
booktitle = "Hematologic Cancers",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Hodgkin lymphoma

T2 - From molecular pathogenesis to targeted therapy

AU - Jóna, Ádám

AU - Illés, A.

AU - Younes, Anas

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 % of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 % of these patients.

AB - Hodgkin lymphoma (HL) is a rare human B-cell lymphoid malignancy representing 11.4 % of all lymphomas in the United States (Jemal et al. 2009) and with an incidence rate of 2.2 per 100,000 in the more developed countries. (Jemal et al. 2011). The treatment of patients with relapsed and refractory HL, especially those who have disease relapse after autologous stem cell transplantation, remains challenging. However current therapy is expected to cure more than 80 % of these patients.

UR - http://www.scopus.com/inward/record.url?scp=85042823170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042823170&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-5028-9_10

DO - 10.1007/978-94-007-5028-9_10

M3 - Chapter

SN - 9789400750272

SP - 181

EP - 202

BT - Hematologic Cancers

PB - Springer Netherlands

ER -